

# Martin O Savage

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1390301/publications.pdf>

Version: 2024-02-01

174  
papers

11,839  
citations

34076

52  
h-index

28275

105  
g-index

185  
all docs

185  
docs citations

185  
times ranked

7175  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1526-1540.	1.8	2,131
2	Intrauterine Growth Retardation and Postnatal Growth Failure Associated with Deletion of the Insulin-Like Growth Factor I Gene. New England Journal of Medicine, 1996, 335, 1363-1367.	13.9	1,002
3	Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2807-2831.	1.8	899
4	Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4210-4217.	1.8	571
5	Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clinical Endocrinology, 1993, 38, 73-78.	1.2	260
6	Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation. Growth Hormone and IGF Research, 2008, 18, 89-110.	0.5	197
7	Clinical Features Affecting Final Adult Height in Patients With Pediatric-Onset Crohn's Disease. Pediatrics, 2006, 118, 124-129.	1.0	180
8	Evidence for a Continuum of Genetic, Phenotypic, and Biochemical Abnormalities in Children with Growth Hormone Insensitivity. Endocrine Reviews, 2011, 32, 472-497.	8.9	171
9	Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.8	157
10	Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 T	1.8	149
11	Phenotype: Genotype Relationships in Growth Hormone Insensitivity Syndrome1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3529-3535.	1.8	137
12	Defects in growth hormone receptor signaling. Trends in Endocrinology and Metabolism, 2007, 18, 134-141.	3.1	134
13	Relationship between Insulin, Insulin-Like Growth Factor I, and Dehydroepiandrosterone Sulfate Concentrations During Childhood, Puberty, and Adult Life*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 932-937.	1.8	132
14	Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends in Endocrinology and Metabolism, 2007, 18, 167-174.	3.1	120
15	Growth in Crohn's disease. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 89-92.	0.7	117
16	A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1686-1690.	1.8	115
17	Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 117-124.	0.7	112
18	Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 39-45.	0.7	112

#	ARTICLE	IF	CITATIONS
19	Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13260-13265.	3.3	111
20	Pseudoexon Activation as a Novel Mechanism for Disease Resulting in Atypical Growth-Hormone Insensitivity. American Journal of Human Genetics, 2001, 69, 641-646.	2.6	110
21	Cushing's Disease in Children and Adolescents: 20 Years of Experience in a Single Neurosurgical Center. Neurosurgery, 2005, 57, 281-285.	0.6	103
22	Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3191-3199.	1.8	103
23	The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1658-1663.	1.8	101
24	Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1407-1411.	1.8	98
25	Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clinical Endocrinology, 1995, 43, 19-28.	1.2	97
26	GONADAL NEOPLASIA AND ABNORMAL SEXUAL DIFFERENTIATION. Clinical Endocrinology, 1990, 32, 519-534.	1.2	93
27	Insulin-Like Growth Factor I Improves Height in Growth Hormone Insensitivity: Two Years&rsquo; Results. Hormone Research, 1995, 44, 253-264.	1.8	93
28	Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. European Journal of Endocrinology, 2011, 164, 667-674.	1.9	93
29	Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet, The, 1997, 350, 1199-1204.	6.3	92
30	Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clinical Endocrinology, 1998, 49, 483-489.	1.2	92
31	Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I. Hormone Research in Paediatrics, 1999, 51, 128-134.	0.8	92
32	Classification of growth hormone insensitivity syndrome. Journal of Pediatrics, 1993, 122, 241.	0.9	91
33	Clinical and Endocrine Responses to Pituitary Radiotherapy in Pediatric Cushing's Disease: An Effective Second-Line Treatment. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 34-37.	1.8	89
34	IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 181-190.	2.2	89
35	The growth hormone&quot;insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocrine Connections, 2018, 7, R212-R222.	0.8	81
36	The continuum of growth hormone&quot;IGF&quot; axis defects causing short stature: diagnostic and therapeutic challenges. Clinical Endocrinology, 2010, 72, 721-728.	1.2	79

#	ARTICLE	IF	CITATIONS
37	Relative Contributions of Inferior Petrosal Sinus Sampling and Pituitary Imaging in the Investigation of Children and Adolescents with ACTH-Dependent Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5711-5714.	1.8	78
38	Relationships between Serum IGF-1, IGFBP-2, Interleukin-1Beta and Interleukin-6 in Inflammatory Bowel Disease. <i>Hormone Research in Paediatrics</i> , 2004, 61, 159-164.	0.8	78
39	Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 395-407.	2.9	78
40	Final adult height and body mass index after cure of paediatric Cushing's disease. <i>Clinical Endocrinology</i> , 2005, 62, 466-472.	1.2	76
41	Prepubertal Cushing's Disease Is More Common in Males, But There Is No Increase in Severity at Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3818-3820.	1.8	75
42	Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3262-3265.	1.8	71
43	Idiopathic short stature: Management and growth hormone treatment. <i>Growth Hormone and IGF Research</i> , 2008, 18, 111-135.	0.5	69
44	The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2291-2297.	1.8	67
45	Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 1611-1616.	1.8	67
46	Noonan's Syndrome: Abnormalities of the Growth Hormone/IGF-I Axis and the Response to Treatment with Human Biosynthetic Growth Hormone. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1991, 80, 446-450.	0.7	65
47	Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1259-1266.	1.8	65
48	Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. <i>European Journal of Endocrinology</i> , 2005, 152, 825-833.	1.9	65
49	Identification and management of poor response to growth-promoting therapy in children with short stature. <i>Clinical Endocrinology</i> , 2012, 77, 169-181.	1.2	59
50	Growth Hormone Therapy and Growth in Children with Noonan's Syndrome: Results of 3 Years' Follow-Up*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1953-1956.	1.8	58
51	Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing's Disease. <i>Hormone Research in Paediatrics</i> , 2005, 64, 140-143.	0.8	58
52	Growth hormone insensitivity: a proposed revised classification. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1999, 88, 147-147.	0.7	55
53	The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1992, 74, 56-63.	1.8	52
54	Androgen secreting adrenocortical tumours. <i>Archives of Disease in Childhood</i> , 1999, 80, 46-50.	1.0	51

#	ARTICLE	IF	CITATIONS
55	Cushing's Disease in Childhood: Presentation, Investigation, Treatment and Long-Term Outcome. <i>Hormone Research in Paediatrics</i> , 2001, 55, 24-30.	0.8	51
56	An Intronic Growth Hormone Receptor Mutation Causing Activation of a Pseudoexon Is Associated with a Broad Spectrum of Growth Hormone Insensitivity Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 655-659.	1.8	51
57	Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome. <i>Hormone Research in Paediatrics</i> , 2001, 55, 125-130.	0.8	50
58	Growth Hormone Insensitivity and Severe Short Stature in Siblings: A Novel Mutation at the Exon 13-Intron 13 Junction of the <i>STAT5b</i> Gene. <i>Hormone Research in Paediatrics</i> , 2007, 68, 218-224.	0.8	49
59	Abnormal puberty in paediatric Cushing's disease: relationship with adrenal androgen, sex hormone binding globulin and gonadotrophin concentrations. <i>Clinical Endocrinology</i> , 2007, 66, 838-843.	1.2	48
60	Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia. <i>Clinical Endocrinology</i> , 2004, 61, 553-559.	1.2	46
61	Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. <i>Clinical Endocrinology</i> , 2004, 60, 163-168.	1.2	46
62	Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 1246-1253.	1.8	45
63	Work-up and management of paediatric Cushing's syndrome. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 346-351.	1.2	44
64	Delayed puberty and response to testosterone in a rat model of colitis. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 281, R1483-R1491.	0.9	43
65	The GH-IGF-I axis in children with idiopathic short stature. <i>Trends in Endocrinology and Metabolism</i> , 2002, 13, 325-330.	3.1	40
66	MANAGEMENT OF ENDOCRINE DISEASE: Paediatric Cushing's disease. <i>European Journal of Endocrinology</i> , 2015, 173, R35-R45.	1.9	40
67	Changes in serum IGF-I and IGFBP-3 concentrations during the IGF-I generation test performed prospectively in children with short stature. <i>Clinical Endocrinology</i> , 1998, 48, 719-724.	1.2	39
68	Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion. <i>Clinical Endocrinology</i> , 2004, 60, 169-174.	1.2	38
69	Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric Cushing's disease. <i>Clinical Endocrinology</i> , 2014, 80, 270-276.	1.2	38
70	Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy. <i>European Journal of Endocrinology</i> , 2007, 156, 477-482.	1.9	37
71	Insulin-Like Growth Factors, Nutrition and Growth. <i>World Review of Nutrition and Dietetics</i> , 2013, 106, 52-59.	0.1	37
72	Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1407-1411.	1.8	37

#	ARTICLE	IF	CITATIONS
73	Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 231-235.	1.8	36
74	Laron syndrome: typical and atypical forms. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1996, 10, 371-387.	1.0	35
75	Early Detection, Referral, Investigation, and Diagnosis of Children with Growth Disorders. <i>Hormone Research in Paediatrics</i> , 2016, 85, 325-332.	0.8	35
76	Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1261-1271.	1.3	34
77	Linear growth and body mass index in pediatric patients with Cushing's disease or simple obesity. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 885-887.	1.8	33
78	Growth Hormone Insensitivity: Pathophysiology, Diagnosis, Clinical Variation and Future Perspectives. <i>Hormone Research in Paediatrics</i> , 2001, 55, 32-35.	0.8	32
79	Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action. <i>Endocrine Reviews</i> , 2019, 40, 476-505.	8.9	32
80	The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome). <i>Clinical Endocrinology</i> , 1993, 39, 119-122.	1.2	30
81	Abnormal Growth in Noonan Syndrome: Genetic and Endocrine Features and Optimal Treatment. <i>Hormone Research</i> , 2008, 70, 129-136.	1.8	30
82	Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity. <i>European Journal of Endocrinology</i> , 2017, 177, 485-501.	1.9	30
83	Growth response to rhIGF-I 80 µg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. <i>Clinical Endocrinology</i> , 1999, 51, 787-792.	1.2	29
84	Therapeutic applications of the insulin-like growth factors. <i>Growth Hormone and IGF Research</i> , 2004, 14, 301-308.	0.5	29
85	A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling. <i>Journal of Endocrinology</i> , 2006, 188, 251-261.	1.2	29
86	Genetic Defects in the Growth Hormone/IGF-I Axis Causing Growth Hormone Insensitivity and Impaired Linear Growth. <i>Frontiers in Endocrinology</i> , 2011, 2, 95.	1.5	29
87	Genetic characterisation of a cohort of children clinically labelled as GH or IGF1 insensitive: diagnostic value of serum IGF1 and height at presentation. <i>European Journal of Endocrinology</i> , 2015, 172, 151-161.	1.9	29
88	Long-term outcomes of children treated for Cushing's disease: a single center experience. <i>Pituitary</i> , 2016, 19, 612-624.	1.6	29
89	The "dawn phenomenon" in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. <i>Clinical Endocrinology</i> , 1995, 43, 567-574.	1.2	28
90	Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease. <i>European Journal of Endocrinology</i> , 2010, 162, 603-609.	1.9	28

#	ARTICLE	IF	CITATIONS
91	Use of Intravenous Etomidate to Control Acute Psychosis Induced by the Hypercortisolaemia in Severe Paediatric Cushing's Disease. <i>Hormone Research in Paediatrics</i> , 2011, 75, 441-446.	0.8	28
92	Cushing's disease in childhood. <i>Trends in Endocrinology and Metabolism</i> , 1996, 7, 213-216.	3.1	27
93	The Discriminatory Value of the Low-Dose Dexamethasone Suppression Test in the Investigation of Paediatric Cushing's Syndrome. <i>Hormone Research in Paediatrics</i> , 2006, 65, 159-162.	0.8	26
94	Novel Dominant-Negative GH Receptor Mutations Expands the Spectrum of GHI and IGF-I Deficiency. <i>Journal of the Endocrine Society</i> , 2017, 1, 345-358.	0.1	26
95	Pediatric Cushing's disease: Management Issues. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, 171.	0.2	26
96	Clinical and endocrine features and long-term outcome of Graves' disease in early childhood. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 388-392.	1.8	25
97	Growth in Disorders of Adrenal Hyperfunction. <i>Hormone Research in Paediatrics</i> , 2002, 58, 39-43.	0.8	24
98	IGFs and IGF-BPs in GH Insensitivity. , 2005, 9, 100-106.		24
99	Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy?. <i>European Journal of Endocrinology</i> , 2007, 157, S33-S37.	1.9	24
100	Magnetic resonance imaging of adrenocortical adenomas in childhood: Correlation with computed tomography and ultrasound. <i>Pediatric Radiology</i> , 1996, 26, 794-799.	1.1	23
101	Transitional care of GH deficiency: when to stop GH therapy. <i>European Journal of Endocrinology</i> , 2004, 151 Suppl 1, S61-S65.	1.9	23
102	Diagnosis and treatment of pediatric Cushing's disease. <i>Pituitary</i> , 2007, 10, 365-371.	1.6	23
103	Acid-Labile Subunit Deficiency and Growth Failure: Description of Two Novel Cases. <i>Hormone Research in Paediatrics</i> , 2010, 73, 328-334.	0.8	23
104	Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 817-835.	2.6	23
105	Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994, 83, 140-141.	0.7	22
106	Acceleration of pubertal development following pituitary radiotherapy for Cushing's disease. <i>Clinical Oncology</i> , 1993, 5, 393-394.	0.6	21
107	Clinical presentation, growth, and pubertal development in Addison's disease.. <i>Archives of Disease in Childhood</i> , 1985, 60, 925-928.	1.0	20
108	Factors Influencing Skeletal Maturation at Diagnosis of Paediatric Cushing's Disease. <i>Hormone Research in Paediatrics</i> , 2007, 68, 231-235.	0.8	20

#	ARTICLE	IF	CITATIONS
109	Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. <i>Clinical Endocrinology</i> , 2020, 92, 98-108.	1.2	20
110	The variability of responses to growth hormone therapy in children with short stature. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, 178.	0.2	20
111	Growth patterns after surgery for virilising adrenocortical adenoma.. <i>Archives of Disease in Childhood</i> , 1992, 67, 234-236.	1.0	19
112	Diagnostic and Therapeutic Advances in Growth Hormone Insensitivity. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 581-595.	1.2	19
113	Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature. <i>Clinical Endocrinology</i> , 2000, 52, 463-469.	1.2	18
114	Phenotypes, Investigation and Treatment of Primary IGF-1 Deficiency. <i>Endocrine Development</i> , 2013, 24, 138-149.	1.3	18
115	Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation. <i>European Journal of Endocrinology</i> , 2018, 178, 481-489.	1.9	17
116	Growth failure: "idiopathic" only after a detailed diagnostic evaluation. <i>Endocrine Connections</i> , 2021, 10, R125-R138.	0.8	17
117	Defects of the growth hormonereceptor and their clinical implications. <i>Growth Hormone and IGF Research</i> , 1999, 9, 57-61.	0.5	16
118	Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity. <i>European Journal of Endocrinology</i> , 2010, 162, 37-42.	1.9	16
119	Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2019, 11, 329-340.	0.4	16
120	Insulin and Growth Factors Adaptation to Normal Puberty. <i>Hormone Research</i> , 1992, 37, 70-73.	1.8	15
121	Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity. <i>Clinical Endocrinology</i> , 2002, 57, 357-361.	1.2	15
122	Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care. <i>Frontiers in Pediatrics</i> , 2021, 9, 715705.	0.9	15
123	Investigation for Paediatric Cushing's Syndrome Using Twenty-Four-Hour Urinary Free Cortisol Determination. <i>Hormone Research in Paediatrics</i> , 2016, 86, 21-26.	0.8	14
124	Advances in the Management of Paediatric Cushing's Disease. <i>Hormone Research in Paediatrics</i> , 2008, 69, 327-333.	0.8	13
125	Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 407-412.	1.8	12
126	Genetic Characterization of Short Stature Patients With Overlapping Features of Growth Hormone Insensitivity Syndromes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4716-e4733.	1.8	11



#	ARTICLE	IF	CITATIONS
127	Digital technologies to improve the precision of paediatric growth disorder diagnosis and management. <i>Growth Hormone and IGF Research</i> , 2021, 59, 101408.	0.5	11
128	The role of corticotrophin-releasing hormone in the diagnosis of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2006, 155, S93-S98.	1.9	10
129	When and how to transfer patients from paediatric to adult endocrinologists: experience from St Bartholomew's Hospital, London. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1997, 86, 127-128.	0.7	9
130	Clinical Spectrum of the Syndrome of Growth Hormone Insensitivity. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1991, 80, 87-90.	0.7	8
131	The investigation of growth hormone insensitivity. <i>Clinical Endocrinology</i> , 1996, 45, 257-260.	1.2	8
132	Diagnosis and management of growth disorders in Gulf Cooperation Council (GCC) countries: Current procedures and key recommendations for best practice. <i>International Journal of Pediatrics and Adolescent Medicine</i> , 2016, 3, 91-102.	0.5	8
133	Should idiopathic short stature be treated with growth hormone?. <i>Nature Reviews Endocrinology</i> , 2009, 5, 148-149.	4.3	7
134	Growth hormone insensitivity syndromes. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1995, 84, 87-90.	0.7	6
135	Luteinizing hormone secreting adrenal tumour as a cause of precocious puberty. <i>Clinical Endocrinology</i> , 1998, 48, 367-372.	1.2	6
136	Normal final height and apparent cure after pituitary irradiation for Cushing's disease in childhood: long-term follow-up of anterior pituitary function. <i>Clinical Endocrinology</i> , 1998, 48, 663-667.	1.2	6
137	Cushing's syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2017, 30, 475-478.	0.4	6
138	The value of whole exome sequencing for genetic diagnosis in a patient with Bloom syndrome. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1331-1334.	1.8	6
139	Managing Paediatric Growth Disorders: Integrating Technology Into a Personalised Approach. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2020, 12, 225-232.	0.4	6
140	Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care. <i>Patient Preference and Adherence</i> , 0, Volume 16, 1663-1671.	0.8	6
141	Novel Growth Hormone Receptor Mutation in a Chinese Patient with Laron Syndrome. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2005, 18, 209-13.	0.4	5
142	Global Inequalities in Paediatric Endocrine Practice: Statement of Minimal Acceptable Care. <i>Hormone Research in Paediatrics</i> , 2006, 65, 111-113.	0.8	5
143	Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. The Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. <i>Acta Paediatrica, International Journal of Paediatrics. Supplement</i> , 1992, 383, 125-6.	1.0	5
144	GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 781044.	1.5	5

#	ARTICLE	IF	CITATIONS
145	Phenotypic Aspects of Growth Hormone- and IGF-I-Resistant Syndromes. <i>Endocrine Development</i> , 2009, 14, 143-150.	1.3	4
146	Diagnosis and Treatment of Cushing's Disease in Children. <i>Endocrine Development</i> , 2009, 17, 134-145.	1.3	4
147	Growth-promoting Hormone Therapy in Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, S135-6.	0.9	4
148	Fundamental principles of clinical and biochemical evaluation underlie the diagnosis and therapy of Cushing's syndrome. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2014, 27, 1029-1031.	0.4	4
149	The continuum between GH deficiency and GH insensitivity in children. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 91-99.	2.6	4
150	Growth Hormone Receptor (GHR) Pseudoexon Activation: A Novel Cause of Severe Growth Hormone Insensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e401-e416.	1.8	4
151	GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6') patients. <i>Endocrine Connections</i> , 2020, 9, 211-222.	0.8	4
152	Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. <i>Diabetes and Metabolism</i> , 1996, 22, 257-60.	1.4	4
153	Final Height in Patients with Idiopathic Short Stature and High Growth Hormone Responses to Stimulation Tests. <i>Hormone Research in Paediatrics</i> , 2007, 67, 224-230.	0.8	2
154	Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 439-441.	1.8	2
155	Pathophysiology, assessment and management of the child with growth hormone resistance. <i>Pediatric Endocrinology Reviews</i> , 2010, 7, 347-56.	1.2	2
156	Patients' Perception of the Use of the EasyPod, Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study. <i>Frontiers in Pediatrics</i> , 2022, 10, 839278.	0.9	2
157	The combined pituitary function test is not indicated in the routine investigation of short stature. <i>Clinical Endocrinology</i> , 2000, 52, 679-679.	1.2	1
158	Diagnosis of pediatric Cushing's syndrome— which test is best?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 76-77.	2.9	1
159	Abnormal growth in noonan syndrome: the challenge of optimal therapy. <i>Pediatric Endocrinology Reviews</i> , 2009, 6 Suppl 4, 523-8.	1.2	1
160	Management of Chronic Systemic Diseases. <i>Hormone Research in Paediatrics</i> , 2007, 68, 112-112.	0.8	0
161	Growth and body composition at diagnosis and postcure in children with Cushing's syndrome. <i>Pediatric Health</i> , 2009, 3, 13-18.	0.3	0
162	Pediatric Cushing Disease. , 2019, , 444-453.		0

#	ARTICLE	IF	CITATIONS
163	Adrenal disorders. , 2007, , .		0
164	Special Aspects of Cushingâ€™s Syndrome: Childhood. , 2010, , 273-282.		0
165	Diagnosis and Treatment of Pediatric Cushingâ€™s Disease. Growth Hormone, 2011, , 197-210.	0.2	0
166	Le continuum des rÃ©sistances Ã  lâ€™hormone de croissance : du retard statural idiopathique au syndrome de Laron. , 2012, , 187-201.		0
167	Growth Hormone Insensitivity Syndrome (GHIS): Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience. Clinical Pediatric Endocrinology, 1994, 3, 115-121.	0.4	0
168	The Clinical and Endocrine Spectrum of Growth Hormone Insensitivity Syndrome (GHIS). Clinical Pediatric Endocrinology, 1994, 3, 245-245.	0.4	0
169	Growth Hormone Insensitivity. , 2018, , 81-93.		0
170	SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease. Journal of the Endocrine Society, 2019, 3, .	0.1	0
171	Growth hormone insensitivity. , 2000, 71, 111-7.		0
172	Phenotypic variability in growth hormone insensitivity. Journal of Pediatric Endocrinology and Metabolism, 2002, 15 Suppl 5, 1449-50.	0.4	0
173	The Changing Face of Paediatric Human Growth Hormone Therapy. Endocrines, 2022, 3, 419-427.	0.4	0
174	Evaluating the sensitivity and specificity of the UK and Dutch growth referral criteria in predicting the diagnosis of pathological short stature. BMJ Paediatrics Open, 2022, 6, e001385.	0.6	0